GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript
Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division K. Gong - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Richard Newitter - Truist Securities, Inc., Research Division Mason Carrico - Stephens Inc., Research Division David Saxon - Needham & Company, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Michael Sarcone - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Alex R. Thurman - Senior VP & CFO Christopher William Lewis - Vice President of Investor Relations & Corporate Affairs Joseph E.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.52 per share a year ago.
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
What Makes Glaukos (GKOS) a New Buy Stock
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
